Ken Wilhelm

1.2k total citations · 1 hit paper
7 papers, 952 citations indexed

About

Ken Wilhelm is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Ken Wilhelm has authored 7 papers receiving a total of 952 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Endocrinology, Diabetes and Metabolism, 4 papers in Molecular Biology and 1 paper in Surgery. Recurrent topics in Ken Wilhelm's work include Diabetes Treatment and Management (6 papers), Diabetes Management and Research (5 papers) and Metabolism, Diabetes, and Cancer (4 papers). Ken Wilhelm is often cited by papers focused on Diabetes Treatment and Management (6 papers), Diabetes Management and Research (5 papers) and Metabolism, Diabetes, and Cancer (4 papers). Ken Wilhelm collaborates with scholars based in United States and Canada. Ken Wilhelm's co-authors include Brandon Walsh, Lisa E. Porter, Carol Wysham, Richard M. Bergenstal, Ping Yan, Leigh MacConell, Jaret Malloy, Michael Trautmann, Kristin Taylor and Terri Kim and has published in prestigious journals such as The Lancet, Diabetes Care and Trends in Endocrinology and Metabolism.

In The Last Decade

Ken Wilhelm

7 papers receiving 899 citations

Hit Papers

Efficacy and safety of exenatide once weekly versus sitag... 2010 2026 2015 2020 2010 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ken Wilhelm United States 6 874 371 336 236 75 7 952
Ted Okerson United States 11 845 1.0× 364 1.0× 479 1.4× 255 1.1× 89 1.2× 21 1.0k
Marilyn K. Boardman United States 10 1.0k 1.2× 470 1.3× 358 1.1× 275 1.2× 84 1.1× 12 1.1k
Fred Yang United States 9 771 0.9× 386 1.0× 300 0.9× 166 0.7× 50 0.7× 17 867
Renee Amori United States 5 772 0.9× 306 0.8× 296 0.9× 157 0.7× 78 1.0× 7 893
Rimma M. Shaginian United States 6 893 1.0× 416 1.1× 404 1.2× 157 0.7× 90 1.2× 8 947
Mario Widel United States 7 764 0.9× 430 1.2× 281 0.8× 139 0.6× 68 0.9× 11 922
Fabrizio Querci Italy 12 525 0.6× 255 0.7× 182 0.5× 123 0.5× 53 0.7× 20 615
Shizuka Kaneko Japan 11 847 1.0× 400 1.1× 291 0.9× 287 1.2× 188 2.5× 23 1.0k
Jorma Strand Denmark 4 759 0.9× 456 1.2× 281 0.8× 196 0.8× 66 0.9× 5 836
Christof Kazda United States 13 836 1.0× 290 0.8× 411 1.2× 234 1.0× 175 2.3× 30 1.0k

Countries citing papers authored by Ken Wilhelm

Since Specialization
Citations

This map shows the geographic impact of Ken Wilhelm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Wilhelm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Wilhelm more than expected).

Fields of papers citing papers by Ken Wilhelm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Wilhelm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Wilhelm. The network helps show where Ken Wilhelm may publish in the future.

Co-authorship network of co-authors of Ken Wilhelm

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Wilhelm. A scholar is included among the top collaborators of Ken Wilhelm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Wilhelm. Ken Wilhelm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Bergenstal, Richard M., Carol Wysham, Leigh MacConell, et al.. (2010). Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. The Lancet. 376(9739). 431–439. 510 indexed citations breakdown →
2.
Buse, John B., Daniel J. Drucker, Kristin Taylor, et al.. (2010). DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care. 33(6). 1255–1261. 282 indexed citations
3.
Malone, James, Michael Trautmann, Ken Wilhelm, Kristin Taylor, & David M. Kendall. (2009). Exenatide once weekly for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs. 18(3). 359–367. 37 indexed citations
4.
Riddle, Matthew C., et al.. (2009). Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes. Diabetes Care. 32(9). 1577–1582. 46 indexed citations
5.
Edelman, Steve, Holly Maier, & Ken Wilhelm. (2008). Pramlintide in the Treatment of Diabetes Mellitus. BioDrugs. 22(6). 375–386. 48 indexed citations
6.
Wysham, Carol, Cameron W. Lush, Bei Zhang, Holly Maier, & Ken Wilhelm. (2007). Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Current Medical Research and Opinion. 24(1). 79–85. 24 indexed citations
7.
Wilhelm, Ken. (2001). Churchill's Pocketbook of Diabetes. Trends in Endocrinology and Metabolism. 12(8). 375–376. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026